Literature DB >> 15816536

HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.

Yasuhiro Ito1, Hiroshi Yoshida, Chisato Tomoda, Akihiro Miya, Kaoru Kobayashi, Fumio Matsuzuka, Kennichi Kakudo, Kanji Kuma, Akira Miyauchi.   

Abstract

BACKGROUND: HBME-1 has been recognized as a useful marker for diagnosing thyroid carcinoma. In this study, we investigated whether it has a diagnostic value for discriminating follicular carcinoma from adenoma.
MATERIALS AND METHODS: We investigated HBME-1 expression in 138 follicular carcinomas, 155 follicular adenomas, 98 adenomatous nodules and 37 papillary carcinomas, using anti-HBME-1 monoclonal antibody.
RESULTS: HBME-1 was positive in 60.9% of follicular carcinoma and the incidence was significantly higher (p<0.0001) than that of follicular adenoma, 30.3%. In adenomatous nodules, only 17.3% were classified as positive, which was lower even than that of follicular adenoma (p=0.0257). All papillary carcinomas examined were positive for HBME-1. We calculated the positive predictive value of HBME-1 in discriminating follicular carcinoma from adenoma as 64.2%.
CONCLUSION: These results suggest that, although HBME-1 contributes to the diagnosis of papillary carcinoma, it could not be applied in the preoperative diagnosis of follicular carcinoma, for example, using fine-needle aspiration biopsy samples.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816536

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Diagnostic utility of immunohistochemical panel in various thyroid pathologies.

Authors:  Arturs Ozolins; Zenons Narbuts; Ilze Strumfa; Guna Volanska; Janis Gardovskis
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

Review 2.  [Clinical importance of thyroid gland cytology].

Authors:  S Ting; S Synoracki; A Bockisch; D Führer; K W Schmid
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

3.  Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions.

Authors:  Hanan AlSaeid Alshenawy
Journal:  Pathol Oncol Res       Date:  2014-03-23       Impact factor: 3.201

Review 4.  Controversies in thyroid pathology: the diagnosis of follicular neoplasms.

Authors:  Stefano Serra; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

5.  Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility.

Authors:  Véronique Hofman; Sandra Lassalle; Christelle Bonnetaud; Catherine Butori; Céline Loubatier; Marius Ilie; Olivier Bordone; Patrick Brest; Nicolas Guevara; José Santini; Brigitte Franc; Paul Hofman
Journal:  Virchows Arch       Date:  2009-06-20       Impact factor: 4.064

6.  Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.

Authors:  C de Micco; V Savchenko; R Giorgi; F Sebag; J-F Henry
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

7.  F12 as a reliable diagnostic and prognostic biomarker associated with immune infiltration in papillary thyroid cancer.

Authors:  Jun-Hua Luo; Xiu-Xia Zhang; Wu-Hui Sun
Journal:  Aging (Albany NY)       Date:  2022-04-28       Impact factor: 5.682

Review 8.  Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.

Authors:  Leandro Luongo de Matos; Adriana Braz Del Giglio; Carolina Ogawa Matsubayashi; Michelle de Lima Farah; Auro Del Giglio; Maria Aparecida da Silva Pinhal
Journal:  Diagn Pathol       Date:  2012-08-13       Impact factor: 2.644

9.  Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.

Authors:  Duško Dunđerović; Jasmina Marković Lipkovski; Ivan Boričic; Ivan Soldatović; Vesna Božic; Dubravka Cvejić; Svetislav Tatić
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.